Analysts set a 12-month price target for PFE at $32.36, citing pipeline strength and a 6.19% dividend yield.
Pfizer (PFE) receives a buy rating with a $32.36 price target, implying 15.27% upside from its recent close of $28.07. The thesis hinges on a 6.19% dividend yield and pipeline momentum, including 19 pivotal study starts in oncology, obesity, and immunology.
Shares trade at 10x forward earnings, a discount to peers like Merck (18x) and Bristol Myers Squibb (11x). Q2 2026 revenue reached $15 billion, with adjusted EPS of 77 cents, and full-year guidance raised to $60.5-$62.5 billion despite a $4.3 billion writedown.
PFE has outperformed year-to-date, rising 18.58%, and closed at $28.07, near its 52-week high of $28.44. CEO Albert Bourla highlighted nine revenue beats in the last ten quarters, reinforcing execution confidence.